Literature DB >> 29444314

Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.

Martin Hasselblatt1, Mohammed Jaber2, David Reuss3,4, Oliver Grauer5, Annkatrin Bibo1, Stephanie Terwey6, Uta Schick6, Heinrich Ebel7, Thomas Niederstadt8, Walter Stummer2, Andreas von Deimling3,4, Werner Paulus1.   

Abstract

The histological and molecular features and even the mere existence of diffuse astrocytoma, IDH-wildtype, remain unclear. We therefore examined 212 diffuse astrocytomas (grade II WHO) in adults using IDH1(R132H) immunohistochemistry followed by IDH1/IDH2 sequencing and neuroimaging review. DNA methylation status and copy number profiles were assessed by Infinium HumanMethylation450k BeadChip. Only 25/212 patients harbored tumors without IDH1/IDH2 hotspot mutations and without contrast enhancement. By DNA methylation profiling, 10/25 tumors were classified as glioblastoma, IDH-wildtype, and an additional 7 cases could not be classified using methylome analysis, but showed genetic characteristics of glioblastoma. Histologically, all of these 17 tumors were low-grade diffuse astrocytomas. Nevertheless, 10/17 patients experienced early malignant progression. Other methylation classes included diffuse midline glioma, H3 K27M-mutant, diffuse astrocytoma, IDH-mutant, pilocytic astrocytoma, and normal or reactive brain tissue (total n = 8). In conclusion, no convincing diffuse astrocytoma, IDH-wildtype, was identified. Most IDH-wildtype tumors showing histopathological and radiological features of low-grade diffuse astrocytoma exhibit molecular and clinical features of high-grade glioma and may represent an early stage of primary glioblastoma. Our findings have implications for the biology, classification and neuropathological diagnosis of diffuse astrocytoma, IDH-wildtype in adults.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29444314     DOI: 10.1093/jnen/nly012

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.148


  22 in total

1.  Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.

Authors:  Tejus A Bale; Justin T Jordan; Otto Rapalino; Nisha Ramamurthy; Nicholas Jessop; John C DeWitt; Valentina Nardi; Maria Martinez-Lage Alvarez; Matthew Frosch; Tracy T Batchelor; David N Louis; A John Iafrate; Daniel P Cahill; Jochen K Lennerz
Journal:  Neuro Oncol       Date:  2019-05-06       Impact factor: 12.300

2.  Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET.

Authors:  Franziska Vettermann; Bogdana Suchorska; Marcus Unterrainer; Debie Nelwan; Robert Forbrig; Viktoria Ruf; Vera Wenter; Friedrich-Wilhelm Kreth; Jochen Herms; Peter Bartenstein; Jörg-Christian Tonn; Nathalie L Albert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-13       Impact factor: 9.236

Review 3.  2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist.

Authors:  Cillian McNamara; Kshitij Mankad; Stefanie Thust; Luke Dixon; Clara Limback-Stanic; Felice D'Arco; Thomas S Jacques; Ulrike Löbel
Journal:  Neuroradiology       Date:  2022-07-22       Impact factor: 2.995

4.  IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups.

Authors:  Roberta Rudà; Francesco Bruno; Tamara Ius; Antonio Silvani; Giuseppe Minniti; Andrea Pace; Giuseppe Lombardi; Luca Bertero; Stefano Pizzolitto; Bianca Pollo; Marco Conti Nibali; Alessia Pellerino; Enrica Migliore; Miran Skrap; Lorenzo Bello; Riccardo Soffietti
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 13.029

5.  IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.

Authors:  Giulia Berzero; Anna Luisa Di Stefano; Susanna Ronchi; Franck Bielle; Chiara Villa; Erell Guillerm; Laurent Capelle; Bertrand Mathon; Alice Laurenge; Marine Giry; Yohann Schmitt; Yannick Marie; Ahmed Idbaih; Khe Hoang-Xuan; Jean-Yves Delattre; Karima Mokhtari; Marc Sanson
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

6.  cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".

Authors:  Daniel J Brat; Kenneth Aldape; Howard Colman; Eric C Holland; David N Louis; Robert B Jenkins; B K Kleinschmidt-DeMasters; Arie Perry; Guido Reifenberger; Roger Stupp; Andreas von Deimling; Michael Weller
Journal:  Acta Neuropathol       Date:  2018-09-26       Impact factor: 17.088

7.  Diagnostic value of PET/CT with 11C-methionine (MET) and 18F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification.

Authors:  Tomoya Ogawa; Nobuyuki Kawai; Keisuke Miyake; Aya Shinomiya; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  EJNMMI Res       Date:  2020-05-07       Impact factor: 3.138

8.  The inverse paradigm and the ancestral cell of IDH-wildtype glioblastoma.

Authors:  Enrico Brognaro
Journal:  Clin Transl Oncol       Date:  2021-06-21       Impact factor: 3.405

9.  Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression.

Authors:  I-Na Lu; Celia Dobersalske; Laurèl Rauschenbach; Sarah Teuber-Hanselmann; Anita Steinbach; Vivien Ullrich; Shruthi Prasad; Tobias Blau; Sied Kebir; Jens T Siveke; Jürgen C Becker; Ulrich Sure; Martin Glas; Björn Scheffler; Igor Cima
Journal:  Nat Commun       Date:  2021-06-23       Impact factor: 14.919

10.  Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes.

Authors:  Hong Guo; Houyi Kang; Haipeng Tong; Xuesong Du; Heng Liu; Yong Tan; Yizeng Yang; Sumei Wang; Weiguo Zhang
Journal:  Eur Radiol       Date:  2018-10-01       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.